State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.
Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Cell Prolif. 2024 Jul;57(7):e13623. doi: 10.1111/cpr.13623. Epub 2024 Mar 3.
The objective of this study was to investigate the effects and molecular mechanisms of tetrahedral framework nucleic acids-microRNA22 (tFNAs-miR22) on inhibiting pathological retinal neovascularization (RNV) and restoring physiological retinal vessels. A novel DNA nanocomplex (tFNAs-miR22) was synthesised by modifying microRNA-22 (miR22) through attachment onto tetrahedral frame nucleic acids (tFNAs), which possess diverse biological functions. Cell proliferation, wound healing, and tube formation were employed for in vitro assays to investigate the angiogenic function of cells. Oxygen-induced retinopathy (OIR) model was utilised to examine the effects of reducing pathological neovascularization (RNV) and inhibiting vascular occlusion in vivo. In vitro, tFNAs-miR22 demonstrated the ability to penetrate endothelial cells and effectively suppress cell proliferation, tube formation, and migration in a hypoxic environment. In vivo, tFNAs-miR22 exhibited promising results in reducing RNV and promoting the restoration of normal retinal blood vessels in OIR model through modulation of the Wnt pathway. This study provided a theoretical basis for the further understanding of RNV, and highlighted the innovative and potential of tFNAs-miR22 as a therapeutic option for ischemic retinal diseases.
本研究旨在探讨四面体框架核酸-微小 RNA22(tFNAs-miR22)抑制病理性视网膜新生血管(RNV)和恢复生理视网膜血管的作用及分子机制。通过将 microRNA-22(miR22)修饰到具有多种生物学功能的四面体框架核酸(tFNAs)上,合成了一种新型 DNA 纳米复合物(tFNAs-miR22)。通过体外细胞增殖、划痕愈合和管形成实验研究了细胞的血管生成功能。利用氧诱导的视网膜病变(OIR)模型研究了体内减少病理性新生血管(RNV)和抑制血管闭塞的效果。体外,tFNAs-miR22 能够穿透内皮细胞,并在缺氧环境下有效抑制细胞增殖、管形成和迁移。在体内,tFNAs-miR22 通过调节 Wnt 通路,在 OIR 模型中表现出减少 RNV 和促进正常视网膜血管恢复的良好效果。本研究为进一步了解 RNV 提供了理论基础,并强调了 tFNAs-miR22 作为缺血性视网膜疾病治疗选择的创新性和潜力。